Status: Not yet recruiting
Trial Without Borders IMPLEMENT-CKD: IMPLEMENTation of Evidence-Based SGLT2i to Reduce Global Burden of Cardiovascular and Chronic Kidney Disease
Chronic kidney disease (CKD) affects millions, especially in low- and middle-income countries, where many die early due to lack of treatment. One group of medicines, called SGLT2 inhibitors (SGLT2i), have been shown to slow down kidney damage and reduce the risk of heart-related deaths. The IMPLEMENT-CKD project will work with communities in Thailand, Fiji and Samoa to make it easier for people with CKD or type 2 diabetes to get these life-saving medicines as part of their regular care.
Participants needed: 1,390
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: The University of QueenslandUpdated: Oct 2, 2026Locations: 3
Eligibility criteria
chronic kidney disease (CKD) with eGFR > 20 mL/min/1.73m²; [+1]
Nil